Clinical Trials Logo

MYD88 Gene Mutation clinical trials

View clinical trials related to MYD88 Gene Mutation.

Filter by:
  • None
  • Page 1

NCT ID: NCT05233033 Suspended - Clinical trials for Diffuse Large B Cell Lymphoma

Safety, PK/PD, and Clinical Activity of KT-413 in Adult Patients With Relapsed or Refractory B-cell NHL

Start date: June 13, 2022
Phase: Phase 1
Study type: Interventional

This Phase 1a/1b study will evaluate the safety, tolerability and the pharmacokinetics/ pharmacodynamics (PK/ PD) of KT-413 in patients with R/R NHL. The Phase 1a stage of the study will explore escalating doses of single-agent KT-413. The Phase 1b stage will be split into 2 expansion cohorts to further characterize the safety, tolerability and the pharmacokinetics/ pharmacodynamics (PK/ PD) of KT-413 in MYD88 mutant and MYD88 wild-type R/R DLBCL.

NCT ID: NCT04994626 Not yet recruiting - Relapse Clinical Trials

Ibrutinib Combined With Rituximab for Treatment of Relapsed Refractory MYD88 and CD79A/B (or CD79B Alone) DLBCL Who Have Received at Least Two Prior Therapies

Start date: October 1, 2021
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of Ibrutinib Combined With Rituximab in Relapsed Refractory MYD88 and CD79A/B (or CD79B Alone) DLBCL Who Have Received at Least Two Prior Therapies.

NCT ID: NCT04273139 Active, not recruiting - Clinical trials for Waldenstrom Macroglobulinemia

Ibrutinib + Venetoclax in Untreated WM

Start date: July 9, 2020
Phase: Phase 2
Study type: Interventional

This study evaluates the safety and efficacy of Ibrutinib combined with Venetoclax (IVEN) in the treatment of adults diagnosed with Waldenstrom's macroglobulinemia (WM) cancer with a specific MYD88 gene mutation. This research study involves an experimental drug combination of targeted therapies. The names of the study drugs involved in this study are: - Venetoclax - ibrutinib